PRRT2

Across TCGA pan-cancer cohorts, PRRT2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRRT2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PRRT2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRRT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, BLCA, and COAD are the cancer types where PRRT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.199	0.730	.002	24	view →
BLCA	DFS	Median	III,IV	0.195	0.574	.026	3	view →
COAD	OS	Median	II,III,IV	0.196	0.788	.010	3	view →
UCEC	DFS	Median	II,III,IV	1.000	0.446	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRRT2–STAD (OS)

Open the STAD breakdown →